Advertisement

It has been more than a decade since Yow-Pin Lim and Douglas Hixson first launched a biomedical company focused on the development of inter-alpha inhibitor proteins, and now he and the team at ProThera Biologics are one step closer to bringing a rapid test to market.

Advertisement
Advertisement